Scarica l'app Stockscreener
5.46
0.36%
-0.02
Xeris Biopharma Holdings Inc Borsa (XERS) Ultime notizie
Transcript : Xeris Biopharma Holdings, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 11 - marketscreener.com
XERS: RECORLEV's rapid growth and pipeline advances drive strong financial and strategic momentum - TradingView
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript - AOL.com
Assessing Xeris Biopharma Holdings (XERS) Valuation After Profitability Milestone And 2026 Revenue Guidance - Sahm
XERS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Momentum Shift: Will Xeris Biopharma Holdings Inc benefit from seasonalityJuly 2025 Update & Stepwise Trade Signal Implementation - baoquankhu1.vn
Xeris Biopharma (NASDAQ:XERS) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat
Xeris Biopharma: Q4 Earnings Snapshot - JG-TC.com
Xeris Biopharma Holdings, Inc. Experiences Evaluation Revision Amid Market Dynamics and Performance Trends - Markets Mojo
Xeris Biopharma Hits Day Low of $5.80 Amid Price Pressure - Markets Mojo
Why Is CORT Stock Falling Today? - Stocktwits
HC Wainwright Forecasts Xeris Biopharma Q1 Earnings - MarketBeat
Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Decoding Xeris Biopharma Holdings Inc (XERS): A Strategic SWOT I - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Insider Sells $104,168.75 in Stock - MarketBeat
Biopharma Appears a Safe Bet Now, So I'm Adding Two Names - TheStreet Pro
Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio (NASDAQ:XERS) - Seeking Alpha
HC Wainwright Predicts Xeris Biopharma Q2 Earnings - MarketBeat
XERS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Xeris Biopharma Balances New Profitability With Recorlev Patent Battles - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Xeris Biopharma’s Q4 2025 earnings beat estimates, stock surges - Investing.com Australia
Xeris Biopharma Holdings, Inc.Common Stock (NQ: XERS - The Chronicle-Journal
Xeris Biopharma Q4 2025 Earnings Call Transcript - MarketBeat
Xeris Biopharma (XERS) Turns Trailing Profitability Into Test Of Bullish Growth Narrative - simplywall.st
Xeris Biopharma Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results - MarketBeat
Beth Hecht 10b5-1 sales reported for XERS (NASDAQ: XERS) - Stock Titan
XERS: Achieved first annual net profit and 43.7% revenue growth, led by Recorlev's strong performance - TradingView
Xeris Biopharma (NASDAQ: XERS) outlines endocrine and neuro focus - Stock Titan
Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highli - GuruFocus
Today's Analyst Update: XERS Rating Reiterated at Buy by HC Wain - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Receives Buy Rating from HC Wainwright - MarketBeat
Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Xeris Biopharma (NASDAQ:XERS) Shares Gap UpHere's What Happened - MarketBeat
Xeris Biopharma Q4 Earnings Call Highlights - MarketBeat
Xeris Biopharma Q4 product revenue USD 83.43 million versus Ibes estimate USD 82.3 million - marketscreener.com
Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
XERS Projects Strong Growth for FY26 with Significant Revenue In - GuruFocus
Xeris (XERS) Sees Strong Q4 Revenue Growth - GuruFocus
(XERS) Xeris Biopharma Expects 2026 Total Revenue Range $375M to $390M, vs. FactSet Est of $368M - marketscreener.com
Earnings Flash (XERS) Xeris Biopharma Holdings, Inc. Reports Q4 Revenue $85.8M, vs. FactSet Est of $82.2M - marketscreener.com
Xeris Bi - Bitget
Earnings Flash (XERS) Xeris Biopharma Posts Q4 EPS $0.06, vs. FactSet Est of $0.02 - marketscreener.com
Xeris Biopharma stock up nearly 3% after Q4 EPS beat, above estimate guidance By Investing.com - Investing.com South Africa
Xeris Biopharma stock up nearly 3% after Q4 EPS beat, above estimate guidance - Investing.com
Xeris Biopharma Reports Record Performance for Q4 and Full Year 2025 - TradingView
XERS: Record 2025 revenue and profitability set the stage for over 30% growth in 2026 - TradingView
Record 2025 results as Xeris Biopharma (XERS) guides for 30%+ 2026 growth - Stock Titan
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance - Business Wire
A Look At Xeris Biopharma Holdings (XERS) Valuation As It Fights To Protect Recorlev Exclusivity - Yahoo Finance
Xeris Biopharma Holdings (XERS) Is Down 7.4% After Suing to Block Recorlev Generics Until 2040 - simplywall.st
Xeris Biopharma (NASDAQ:XERS) Trading Down 8.3%Should You Sell? - MarketBeat
Why Are Shares Of Xeris Biopharma Falling Friday? - Benzinga
Xeris Biopharma Holdings Enters Oversold Territory (XERS) - Nasdaq
Xeris Pharmaceuticals (XERS) Set to Announce Q4 Earnings with St - GuruFocus
A Peek at Xeris Biopharma Holdings's Future Earnings - Benzinga
Pullback Watch: Can Xeris Biopharma Holdings Inc keep up with sector leadersJuly 2025 PreEarnings & Low Volatility Stock Suggestions - baoquankhu1.vn
Xeris Biopharma Sues Torrent Pharmaceuticals, Somerset Therapeutics Over Recorlev Patents - marketscreener.com
Xeris Biopharma subsidiaries file Recorlev patent infringement lawsuit - marketscreener.com
Xeris Biopharma Files Patent Infringement Lawsuit Over Recorlev Used for Endogenous Cushing’s Syndrome - geneonline.com
Xeris Biopharma (XERS) Sues Over Recorlev Patent Dispute - GuruFocus
[8-K] Xeris Biopharma Holdings, Inc. Reports Material Event | XERS SEC FilingForm 8-K - Stock Titan
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):